Clinical trial
Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating…
NCT00068250 · Radiation Therapy Oncology Group, Other · Completed
Key facts
| NCT number | NCT00068250 |
|---|---|
| Title | Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma |
| Official title | Phase I/II Study Of Pre-Irradiation Chemotherapy With Methotrexate, Rituximab, And Temozolomide And Post -Irradiation Temozolomide For Primary Central Nervous System Lymphoma |
| Lead sponsor | Radiation Therapy Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH NRG Oncology |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors, Lymphoma |
| Intervention type | Drug, Radiation |
| Interventions | rituximab, methotrexate, temozolomide 100 mg/m^2, temozolomide 150 mg/m^2, temozolomide 200 mg/m^2, radiation therapy, post-radiation therapy temozolomide |
| Enrollment | 60 |
| Start date | Jul 1, 2003 |
| Primary completion | Dec 1, 2016 |
| Completion | Dec 1, 2016 |
| First posted | Sep 11, 2003 |
| Last update posted | Feb 7, 2018 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: